A. L. O. Granados

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).

J. Bosch-Barrera, R. Rosell, N. Reguart, 2020, Lung cancer.

OA01.07 A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC

E. Schmidt, E. Felip, H. Gabra, 2021 .